Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  The Lancet

• Publication date

  1999-03-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(05)76666-6PMID 10459993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation.

  1998cited by this paper
• Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma

  1997cited by this paper
• Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.

  1991cited by this paper
• Erythromycin is a motilin receptor agonist.

  1989cited by this paper

• A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant

  2021cites this paper
• Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update

  2021cites this paper
• Clinical Observation of the Dispelling Turbid Qi and Stopping Nausea and Vomit Decoction in Prevention of Nausea and Vomiting in Chemotherapy with Cisplatin

  2020cites this paper
• The use of octreotide to manage symptoms of bronchorrhea: a case report.

  2014cites this paper
• Established and potential therapeutic applications of octreotide in palliative care

  2008cites this paper
• Antiemetic therapy.

  2002cites this paper
• The role of octreotide in symptom management in oncology and palliative care

  2000cites this paper
• The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury.

  1999cites this paper